Back to top
more

MacroGenics, Inc. (MGNX)

(Delayed Data from NSDQ)

$20.80 USD

20.80
1,762,276

-0.53 (-2.48%)

Updated Jun 14, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 24% (191 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for MGNX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for MacroGenics, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents 273 216 233 305 277
Receivables 23 13 30 14 3
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 17 11 7 4 4
Total Current Assets 313 240 269 322 284
Net Property & Equipment 42 48 57 50 18
Investments & Advances 0 0 0 0 8
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 24 25 6 2 1
Total Assets 379 313 332 374 311
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable 0 0 0 0 0
Accounts Payable 8 4 4 2 4
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 34 27 33 39 16
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 4 11 23 8 6
Total Current Liabilities 51 45 60 50 27
Mortgages 0 0 0 0 0
Deferred Taxes/Income 7 9 29 25 15
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 83 82 89 75 43
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 0 0 0 0
Capital Surplus 1,067 872 733 611 561
Retained Earnings -772 -642 -490 -312 -293
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 296 231 243 299 269
Total Liabilities & Shareholder's Equity 379 313 332 374 311
Total Common Equity 296 231 243 299 269
Shares Outstanding 56.20 48.90 42.20 36.80 34.80
Book Value Per Share 5.26 4.72 5.76 8.13 7.72

Fiscal Year End for MacroGenics, Inc. falls in the month of December.

All items in Millions except Per Share data.

3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Assets          
Cash & Equivalents 343 273 281 233 171
Receivables 7 23 19 19 12
Notes Receivable 0 0 0 0 0
Inventories 6 0 0 0 0
Other Current Assets 18 17 11 8 13
Total Current Assets 375 313 310 260 195
Net Property & Equipment 40 42 41 44 46
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 20 24 23 24 24
Total Assets 435 379 374 328 265
Liabilities & Shareholders Equity 3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Notes Payable 0 0 0 0 0
Accounts Payable 10 8 4 3 2
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 35 34 33 30 25
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 4 4 9 9 10
Total Current Liabilities 53 51 50 46 40
Mortgages 0 0 0 0 0
Deferred Taxes/Income 7 7 6 7 8
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 2 1 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 85 83 83 80 75
Shareholders Equity 3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 0
Capital Surplus 1,173 1,067 1,061 981 877
Retained Earnings -823 -772 -770 -734 -687
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 351 296 292 248 191
Total Liabilities & Shareholder's Equity 435 379 374 328 265
Total Common Equity 351 296 292 248 191
Shares Outstanding 60.00 56.20 56.20 54.10 49.10
Book Value Per Share 5.84 5.26 5.19 4.58 3.88